2021
Gamma–Delta T‐cell Lymphomas
Foss F, Ahmed A, Xu M. Gamma–Delta T‐cell Lymphomas. 2021, 203-210. DOI: 10.1002/9781119671336.ch15.Peer-Reviewed Original ResearchGamma-delta T-cell lymphomaT-cell lymphomaHepatosplenic T-cell lymphomaPrimary cutaneous gamma-delta T-cell lymphomaCutaneous gamma-delta T-cell lymphomaFive-year overall survivalCentral nervous system prophylaxisGamma delta T cellsWorld Health Organization classificationAggressive T-cell lymphomaExtensive skin ulcerationsCurative stem cell transplantationChronic antigenic stimulationStem cell transplantationInnate immune systemMost chemotherapeutic agentsSystemic methotrexateSystem prophylaxisMedian survivalMost patientsOverall prognosisOverall survivalClinical featuresOrganization classificationRisk factors
2013
Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience
Fraser J, Subtil A, Alpdogan O, Seropian S, Cooper D, Xu M, Foss F. Cytotoxic and Gamma-Delta Subtypes Of Peripheral T-Cell Lymphoma: A Single Center Experience. Blood 2013, 122: 5092. DOI: 10.1182/blood.v122.21.5092.5092.Peer-Reviewed Original ResearchGamma-delta T-cell lymphomaT-cell lymphomaCutaneous gamma-delta T-cell lymphomaHepatosplenic T-cell lymphomaPeripheral T-cell lymphomaStem cell transplantationInitial therapyCell transplantationLymphoid neoplasmsPrimary cutaneous gamma-delta T-cell lymphomaGamma delta T-cell receptorInitiation of chemotherapySingle-center experienceAggressive clinical courseOff-label useT-cell NHLT cell receptorAdvisory CommitteeAcute GVHDAlloBMT patientsMedian followSalvage therapyAdditional therapyB symptomsFirst remission